NGL Fine-Chem Limited

BSE: 524774 NSE: NGLFINE
NGL Fine-Chem Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24110MH1981PLC025884 Incorporated 18 December 1981 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: NGLFINE · BSE: 524774 Public Limited Company pharma
Data last updated
Market Cap
₹1,635 Cr
NGLFINE · NSE
Share Price
₹2,616.30
-1.09% today
Revenue
₹501 Cr
FY 2025-26 · +36.0% YoY
EBITDA
₹73.34 Cr
Margin 14.6%
Net Profit
₹53.20 Cr
FY 2025-26 · +149.8% YoY
P/E (TTM)
28.3x
P/B 4.9x
ROE
17.4%
ROCE 18.3%
Debt / Equity
0.33
Interest cover 9.5x

About NGL Fine-Chem Limited

Data last updated:

NGL Fine-Chem Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the animal pharmaceuticals and healthcare segment of the pharmaceuticals sector. It was incorporated on 18 December 1981 and has been in existence for over 45 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24110MH1981PLC025884. Its GSTIN is 27AAACN4805H1ZM (Maharashtra). It is a listed company as per MCA records. Its shares are listed on BSE: 524774 and NSE: NGLFINE.

The company has an authorised share capital of ₹5 Cr and a paid-up capital of ₹3.09 Cr. It was formerly known as Angel Organic Chemicals Pvt Ltd and Angel Organic Chemicals Ltd. It is led by directors including Rahul Jayant Nachane (Managing Director) and Rajesh Narayan Lawande (Whole-Time Director).

Its last annual general meeting (AGM) was held on 19 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 301 E Square Subhash Road Vile Parle (East), Mumbai, Maharashtra, India – 400057.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹500.95 Cr, a growth of 36% compared to the previous year. For the same year it recorded a net profit of ₹53.2 Cr (net margin 10.6%) and EBITDA of ₹73.34 Cr (EBITDA margin 14.6%). The net worth stands at ₹329.24 Cr (up 16.6% YoY). Total assets are valued at ₹460.09 Cr (up 25.8% YoY).

The company has about 363 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.

The company is associated with 1 brand: NGL Fine Chem. As per MCA filings, the company has open charges of ₹117.75 Cr and satisfied charges of ₹53.89 Cr on record. Court records list 12 cases involving the company, including 5 filed by the company and 7 filed against it; 5 cases are pending. The company has 4 deals on record (4 market trades); the latest was in April 2016. Its 9 peer companies in the Pharma industry (Animal Pharma, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 5 smaller; the largest is Zim Laboratories Limited. with revenue of ₹384.82 Cr. The company has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 7 overdue payments to 7 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website nglfinechem.com.

Company details

CIN L24110MH1981PLC025884
Registration Number 025884
Incorporation Date 18 December 1981
ROC Mumbai
Listing Status Listed - Listed on NSE (NGLFINE); Listed on BSE (524774)
Company Status Active
Date of Last AGM 19 August 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

Name history

NGL Fine-Chem has undergone 2 name changes throughout its history. The company was previously known as Angel Organic Chemicals Pvt Ltd, and Angel Organic Chemicals Ltd. The current legal name is Ngl Fine-Chem Limited.

Company NameStatus
NGL Fine-Chem LimitedCurrent
Angel Organic Chemicals Pvt LtdPrevious
Angel Organic Chemicals LtdPrevious

CIN history

NGL Fine-Chem has one previous CIN (Corporate Identification Number): U24110MH1981PTC025884. The current CIN is L24110MH1981PLC025884, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24110MH1981PLC025884Current
U24110MH1981PTC025884Previous
Key People
Rahul Jayant Nachane Managing Director Rajesh Narayan Lawande Whole-Time Director Ajita Rahul Nachane Director

Contact details

NGL Fine-Chem Limited's registered office is in Mumbai, Maharashtra. Its website is nglfinechem.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    nglfinechem.com
  • Social Media
  • Registered Address
    301 E Square Subhash Road Vile Parle (East), Mumbai, Maharashtra, India – 400057
  • Industry
    Pharma, Animal Pharmaceuticals & Healthcare, Drug Formulation & Development

To see the full contact details of NGL Fine-Chem Limited, buy the company report.

Comprehensive company report
NGL Fine-Chem Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

NGL Fine-Chem operates one associated brand: NGL Fine Chem. Each brand links to its own profile.

BrandDescriptionWebsite
NGL Fine Chem
CDMO specializing in multi stage organic synthesis of generic APIs and fine chemicalsnglfinechem.com

Business activity

The main business activity of NGL Fine-Chem is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of NGL Fine-Chem Limited, buy the company report.

Financials of NGL Fine-Chem Limited

FY 2025-26 filings available

NGL Fine-Chem Limited reported revenue of ₹500.95 Cr (up 36% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹501 Cr
+36.0% YoY
EBITDA
₹73.34 Cr
+110.7% YoY
Profit After Tax
₹53.20 Cr
+149.8% YoY
Net Worth
₹329 Cr
+16.6% YoY
Total Assets
₹460 Cr
+25.8% YoY
Total Debt
₹123 Cr
+57.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue501368339278318258152
Revenue growth+36.0%+8.7%+21.8%-12.4%+23.1%+70.1%-
EBITDA73.3434.8053.7534.9668.1980.1019.77
EBITDA margin+14.6%+9.5%+15.9%+12.6%+21.5%+31.1%+13.0%
Profit before tax63.3627.7254.4327.3766.5977.5912.08
Net profit53.2021.3041.3220.5049.8956.729.69
Net profit margin+10.6%+5.8%+12.2%+7.4%+15.7%+22.0%+6.4%
EPS (₹)77.9034.1966.8833.1880.7791.8113.49
Balance sheet
Total assets460366300258236174130
Net worth32928226322320315498.96
Total debt12377.6734.0032.5030.0016.4528.24
Cash & bank5.114.971.7213.040.834.783.16
Net working capital15310810695.3210664.0147.08
Cash flow
Cash from operations43.3232.3520.4735.2913.8227.3520.46
Cash from investing(70.59)(69.68)(26.82)(27.02)(14.20)(24.57)(19.55)
Cash from financing29.5537.47(1.08)(1.08)(1.08)(1.08)(1.30)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue13914912812010494.9789.1093.48
Revenue growth (YoY)+33.6%+57.1%+43.1%+28.7%+14.8%---
Other income7.432.464.612.056.35(0.97)(0.13)5.12
EBITDA23.2821.4122.3117.1610.986.325.1011.55
EBITDA margin+16.7%+14.3%+17.5%+14.3%+10.5%+6.7%+5.7%+12.4%
Depreciation5.255.055.185.094.273.323.103.03
Interest0.991.011.071.161.220.970.600.32
Profit before tax24.4717.8120.6712.9611.841.061.2713.32
Tax6.084.324.983.342.600.52(0.01)3.52
Net profit18.3913.4915.699.629.240.541.289.80
EPS (₹)29.7821.8325.4015.5814.960.882.0715.88
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue489359329275319258152
Revenue growth+36.0%+9.2%+19.6%-13.7%+23.4%+69.7%-
EBITDA61.0926.5744.7728.7265.9277.0520.92
EBITDA margin+12.5%+7.4%+13.6%+10.4%+20.7%+29.8%+13.8%
Profit before tax54.6123.8850.7226.6068.9876.0114.37
Net profit46.7118.3038.5320.1252.2555.4812.11
Net profit margin+9.6%+5.1%+11.7%+7.3%+16.4%+21.5%+8.0%
EPS (₹)67.3929.3562.3532.5784.5789.7917.16
Balance sheet
Total assets449361300261239175132
Net worth320280263226207155101
Total debt12276.5134.0032.5030.0016.4528.24
Cash & bank2.754.861.6012.950.744.703.07
Net working capital14710699.0093.5010565.5149.11
Cash flow
Cash from operations34.7321.9911.1431.8912.6926.5719.62
Cash from investing(64.57)(58.20)(17.49)(23.62)(13.00)(23.79)(18.78)
Cash from financing29.8736.35(1.08)(1.08)(1.08)(1.08)(1.30)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue13714512611710193.0286.8391.41
Revenue growth (YoY)+35.5%+55.6%+45.5%+27.8%+14.6%---
Other income7.362.514.692.416.55(0.79)0.155.43
Total expenses11712710610393.0489.1183.2880.79
EBITDA19.7817.6020.0913.677.823.913.5510.62
EBITDA margin+14.5%+12.2%+15.9%+11.7%+7.8%+4.2%+4.1%+11.6%
Depreciation4.434.244.354.263.452.532.212.30
Interest0.970.991.061.151.210.950.690.32
Profit before tax21.7414.8819.3710.679.71(0.36)0.8013.43
Tax5.293.524.642.762.070.160.033.39

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 26 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue13914912812010494.9789.1093.48
Revenue growth (YoY)+33.6%+57.1%+43.1%+28.7%+14.8%---
Other income7.432.464.612.056.35(0.97)(0.13)5.12
EBITDA23.2821.4122.3117.1610.986.325.1011.55
EBITDA margin+16.7%+14.3%+17.5%+14.3%+10.5%+6.7%+5.7%+12.4%
Depreciation5.255.055.185.094.273.323.103.03
Interest0.991.011.071.161.220.970.600.32
Profit before tax24.4717.8120.6712.9611.841.061.2713.32
Tax6.084.324.983.342.600.52(0.01)3.52
Net profit18.3913.4915.699.629.240.541.289.80
EPS (₹)29.7821.8325.4015.5814.960.882.0715.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue501368339278318258152
Revenue growth+36.0%+8.7%+21.8%-12.4%+23.1%+70.1%-
Other income14.738.6314.135.5310.688.023.05
Total expenses428333285243249178132
Employee cost65.5055.5545.1236.8734.8528.0924.04
EBITDA73.3434.8053.7534.9668.1980.1019.77
EBITDA margin+14.6%+9.5%+15.9%+12.6%+21.5%+31.1%+13.0%
Depreciation19.5812.4511.6411.2910.378.338.11
Interest5.133.261.811.831.912.202.63
Profit before tax63.3627.7254.4327.3766.5977.5912.08
Tax15.246.5913.116.8716.7020.873.73
Net profit53.2021.3041.3220.5049.8956.729.69
Net profit margin+10.6%+5.8%+12.2%+7.4%+15.7%+22.0%+6.4%
EPS (₹)77.9034.1966.8833.1880.7791.8113.49
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital3.093.093.093.093.093.093.09
Reserves & surplus32627926021920015195.87
Shareholders' funds (net worth)32928226322320315498.96
Minority interest0.000.000.000.000.000.000.00
Secured loans12277.2834.0030.4826.8616.4522.93
Unsecured loans0.080.390.002.023.140.005.31
Total debt12377.6734.0032.5030.0016.4528.24
Total liabilities460366300258236174130
Assets
Gross block25621714813913095.9691.81
Net block16414385.5787.9188.7864.1367.74
Capital work in progress94.5749.7345.5226.316.4312.350.00
Investments39.1959.6653.5939.4628.7229.0710.65
Inventories70.2851.2743.3026.9956.0137.8527.90
Sundry debtors13182.8489.6265.8763.9837.5626.19
Cash & bank balances5.114.971.7213.040.834.783.16
Loans & advances30.9335.1324.4317.2923.9615.2712.96
Total current assets23717415912314595.4670.21
Total current liabilities83.8366.4853.3327.8739.0931.4523.13
Net working capital15310810695.3210664.0147.08
Total assets460366300258236174130
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.530.407.830.642.100.400.79
Net cash from operating activities43.3232.3520.4735.2913.8227.3520.46
Net cash from investing activities(70.59)(69.68)(26.82)(27.02)(14.20)(24.57)(19.55)
Net cash from financing activities29.5537.47(1.08)(1.08)(1.08)(1.08)(1.30)
Net change in cash2.270.14(7.43)7.18(1.46)1.70(0.39)
Closing cash5.114.971.7213.040.834.783.16
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+36.0%+8.7%+21.8%-12.4%+23.1%+70.1%-
EBITDA growth+110.8%-35.3%+53.8%-48.7%-14.9%+305.2%-
PBT growth+128.6%-49.1%+98.9%-58.9%-14.2%+542.3%-56.2%
Net income growth+149.8%-48.5%+101.6%-58.9%-12.0%+485.4%-
Revenue CAGR (3Y)+21.7%+5.1%+9.5%+22.4%+27.5%--
EBITDA CAGR (3Y)+28.0%-20.1%-12.5%+20.9%+28.3%--
Profitability & leverage
Net income margin+9.6%+5.7%+12.2%+7.4%+15.7%+22.0%+5.5%
Return on capital employed+18.3%+9.3%+20.2%+11.8%+33.5%+52.7%+13.5%
Return on net worth+17.4%+7.8%+17.0%+9.6%+27.9%+44.8%+10.1%
Debt / equity0.330.200.140.150.130.180.29
Long-term debt / equity0.130.050.010.010.030.060.09
Interest cover9.5414.594.307.733.303.0722.56
Efficiency & per share
Fixed asset turnover2.122.022.362.072.822.751.83
Inventory turnover8.247.799.646.706.777.856.52
Debtors turnover4.694.274.364.286.258.095.12
EPS (₹)77.9034.1966.8833.1880.7791.8113.49
Dividend per share (₹)1.751.751.751.751.751.751.75
Book value per share (₹)532.92457.16425.11360.23328.94250.01160.18
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue13714512611710193.0286.8391.41
Revenue growth (YoY)+35.5%+55.6%+45.5%+27.8%+14.6%---
Other income7.362.514.692.416.55(0.79)0.155.43
Total expenses11712710610393.0489.1183.2880.79
EBITDA19.7817.6020.0913.677.823.913.5510.62
EBITDA margin+14.5%+12.2%+15.9%+11.7%+7.8%+4.2%+4.1%+11.6%
Depreciation4.434.244.354.263.452.532.212.30
Interest0.970.991.061.151.210.950.690.32
Profit before tax21.7414.8819.3710.679.71(0.36)0.8013.43
Tax5.293.524.642.762.070.160.033.39
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue489359329275319258152
Revenue growth+36.0%+9.2%+19.6%-13.7%+23.4%+69.7%-
Other income14.859.7615.907.6112.648.553.34
Total expenses428333284246253181131
Employee cost60.2550.7141.3234.2533.0527.2423.81
EBITDA61.0926.5744.7728.7265.9277.0520.92
EBITDA margin+12.5%+7.4%+13.6%+10.4%+20.7%+29.8%+13.8%
Depreciation16.309.278.157.907.677.397.27
Interest5.033.181.801.831.912.202.62
Profit before tax54.6123.8850.7226.6068.9876.0114.37
Tax12.995.7512.196.4816.7320.533.75
Net profit46.7118.3038.5320.1252.2555.4812.11
Net profit margin+9.6%+5.1%+11.7%+7.3%+16.4%+21.5%+8.0%
EPS (₹)67.3929.3562.3532.5784.5789.7917.16
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital3.093.093.093.093.093.093.09
Reserves & surplus31727726022220315298.12
Shareholders' funds (net worth)320280263226207155101
Secured loans12276.1234.0030.4830.0016.4522.93
Unsecured loans0.080.390.002.020.000.005.31
Total debt12276.5134.0032.5030.0016.4528.24
Total liabilities449361300261239175132
Assets
Gross block21517710810092.1284.7581.25
Net block14412060.1359.4958.6757.5360.85
Capital work in progress94.5749.7345.5226.316.310.910.00
Investments42.9163.3957.3243.1932.4532.8014.38
Inventories67.6349.0742.6026.9655.1237.8527.90
Sundry debtors12579.7783.1365.1864.9037.5626.19
Cash & bank balances2.754.861.6012.950.744.703.07
Loans & advances30.2234.1922.7714.6320.5614.2914.83
Total current assets22616815012014194.4071.99
Total current liabilities78.7662.1751.1026.2236.5528.8922.88
Net working capital14710699.0093.5010565.5149.11
Total assets449361300261239175132
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.520.397.820.642.030.330.79
Net cash from operating activities34.7321.9911.1431.8912.6926.5719.62
Net cash from investing activities(64.57)(58.20)(17.49)(23.62)(13.00)(23.79)(18.78)
Net cash from financing activities29.8736.35(1.08)(1.08)(1.08)(1.08)(1.30)
Net change in cash0.030.14(7.44)7.19(1.40)1.71(0.46)
Closing cash2.754.861.6012.950.744.703.07
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+36.0%+9.2%+19.6%-13.7%+23.4%+69.7%-
EBITDA growth+129.9%-40.7%+55.9%-56.4%-14.5%+268.3%-
PBT growth+128.7%-52.9%+90.7%-61.4%-9.3%+429.0%-47.9%
Net income growth+155.3%-52.5%+91.5%-61.5%-5.8%+358.1%-
Revenue CAGR (3Y)+21.1%+4.1%+8.4%+21.8%+27.7%+31.5%+15.1%
EBITDA CAGR (3Y)+28.6%-26.1%-16.6%+11.1%+26.9%+52.9%-6.4%
Profitability & leverage
Net income margin+8.5%+5.1%+11.7%+7.3%+16.4%+21.5%+7.0%
Return on capital employed+16.4%+8.2%+18.7%+11.4%+34.3%+51.1%+15.2%
Return on net worth+15.6%+6.7%+15.8%+9.3%+28.9%+43.2%+12.5%
Debt / equity0.330.200.140.140.130.170.29
Long-term debt / equity0.140.050.010.010.030.060.08
Interest cover11.2318.384.928.793.283.1619.19
Efficiency & per share
Fixed asset turnover2.502.523.152.863.603.111.96
Inventory turnover8.387.849.466.706.867.856.54
Debtors turnover4.764.414.444.236.228.105.13
EPS (₹)67.3929.3562.3532.5784.5789.7917.16
Dividend per share (₹)1.751.751.751.751.751.751.75
Book value per share (₹)517.86452.60425.39365.04334.36251.62163.81

To see the full year-wise statements and ratios of NGL Fine-Chem Limited, buy the company report.

Board of directors of NGL Fine-Chem Limited

NGL Fine-Chem has 6 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Ajita Rahul Nachane
Also directs: Tele Access E-Services Private Limited
Director15 Sep 201412 Years 1 MonthsCurrent
Rahul Jayant Nachane
Also directs: Macrotech Polychem Private Limited, Nupur Remedies Pvt Ltd, Vetfar Pharmaceuticals Private Limited and 1 more
Managing Director04 Jan 199333 Years 9 MonthsCurrent
Sarala Menon
Also directs: Aretian Business Consulting LLP
Director14 Dec 20214 Years 10 MonthsCurrent
Rajesh Narayan Lawande
Also directs: Macrotech Polychem Private Limited, Nupur Remedies Pvt Ltd, Vetfar Pharmaceuticals Private Limited
Whole-Time Director01 Jun 201511 Years 4 MonthsCurrent
Sudhir Ramchandra Deo
Also directs: Navin Fluorine International Limited
Director22 May 20251 Years 5 MonthsCurrent
Dhananjay Narendra Mungale
Also directs: Kalpataru Projects International Limited, Symbiotec Pharmalab Limited, Lichfl Asset Management Company Limited and 4 more
Director18 Mar 20242 Years 7 MonthsCurrent
View all directors

Peer comparison

NGL Fine-Chem Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Animal Pharma, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
NGL Fine-Chem Limitedthis company₹500.95 Cr (FY 2026)₹53.2 Cr10.6%36.0%363Mumbai, Maharashtra, India
Zim Laboratories Limited.₹384.82 Cr (FY 2025)3.0%Nagpur, Maharashtra, India
Rajasthan Antibiotics Ltd₹383.3 Cr (FY 2025)1.0%New Delhi, Delhi, India
Marc Laboratories Limited₹383.21 Cr (FY 2025)3.0%New Delhi, Delhi, India
Caplin Steriles Limited₹377.24 Cr (FY 2025)18.0%Chennai, Tamil Nadu, India
Unicure India Ltd₹369.12 Cr (FY 2025)-12.0%New Delhi, Delhi, India
Beta Drugs Limited₹368.79 Cr (FY 2025)24.0%Baddi, Himachal Pradesh, India
Brawn Laboratories Limited₹368.56 Cr (FY 2025)15.0%Delhi, India
M. J. Biopharm Private Limited₹367.26 Cr (FY 2025)24.0%Pune, Maharashtra, India
Biochem Pharmaceutical Industries Limited Part IX₹366.61 Cr (FY 2016)15.0%Ahmedabad, Gujarat, India

To see the full peer comparison of NGL Fine-Chem Limited, buy the company report.

Auditor

NGL Fine-Chem Limited is audited by Manek & Associates for the financial year 2023.

Auditor firmFinancial yearFirm registration number
Manek & AssociatesFY 2023126679W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 72.50%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.10% and retail and other public shareholders hold 27.40%.

Promoters: 72.50%DII (Domestic Institutional): 0.10%Retail & Others: 27.40%
Sep 2026
QUARTER
72.50% Promoters
0.10% DII (Domestic Institutional)
27.40% Retail & Others
Promoter holding - history
Now 72.50% · Sep 2026High 72.70% · Dec 2025Low 72.50% · Sep 2026
71%71.8%72.5%73.3%74%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 72.70%Mar 2026: 72.70%Jun 2026: 72.70%Sep 2026: 72.50%72.70%72.50%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters72.50%72.70%72.70%72.70%
Public27.50%27.30%27.30%27.30%

Charges & borrowings

Open charges
₹117.75 Cr
Satisfied charges
₹53.89 Cr
Breakdown by lending institutions
Hdfc Bank Limited₹67.25 Cr
Others₹50.50 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
29 Nov 2023100829654Hdfc Bank Limited₹25 LakhOpen
02 Aug 2022100603458Others₹50.5 CrOpen
07 Dec 201510613804Hdfc Bank Limited₹67 CrOpen
10 Mar 2022100555031Hdfc Bank Limited₹30 LakhSatisfied
30 Aug 2021100476181Hdfc Bank Limited₹19 LakhSatisfied

To see the full charge records of NGL Fine-Chem Limited, buy the company report.

Total charge records: 30 View all charges

Deals & funding

NGL Fine-Chem Limited has 4 deals on record (4 market trades); the latest was in April 2016.

Total deals
4
Market trades
4

Deals on record (4 of 4)

WhenDealAmountParties
Apr 2016Market trade₹2.07 CrBuyer: J S L Enterprises
Seller: Uphar Homefin Private Limited
Jun 2015Market trade₹98.2 LakhBuyer: an individual
Seller: Shaktiman Steel Casting Pvt Ltd.
Mar 2013Market trade₹4.3 LakhSeller: an individual
Jul 2010Market trade₹44.8 LakhBuyer: Arya Investments, NBN Fintrade Private Limited
Seller: NBN Fintrade Private Limited , Arya Investments, an individual

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

NGL Fine-Chem Limited was last rated by Icra on 23 Dec 2021.

Rating agencyRated onRating
Icra23 Dec 2021

To see the full credit ratings and regulatory alerts of NGL Fine-Chem Limited, buy the company report.

MSME payment delays

NGL Fine-Chem Limited has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 7 overdue payments to 7 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 7)

SupplierAmount dueDue sinceReported on
Vinayak Traders
an individual supplier
an individual supplier
Karrat Chemicals (India) Private Limited
Fabricraft

To see the full MSME payment records of NGL Fine-Chem Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

NGL Fine-Chem has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

1
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Macrotech Polychem Private LimitedU24100MH2004PTC145189

To see the full group structure of NGL Fine-Chem Limited, buy the company report.

Employees & EPFO

NGL Fine-Chem Limited has a workforce of 363 employees on its EPFO records as of Apr 08, 2024, across 2 active EPFO establishments.

Employee count
363
Active EPFO establishments
2
Employee growth
6.76%

GST

NGL Fine-Chem has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
27AAACN4805H1ZMMaharashtraActive01 Jul 2017

To see the full GST registrations and return filing status of NGL Fine-Chem Limited, buy the company report.

Recent activity

NGL Fine-Chem Limited has 20 board changes on record since 1993: 13 appointments and 7 cessations. The latest: Jayaram Sitaram ceased to be Director on 04 Aug 2025.

Filing
Ngl Fine-Chem Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
Charges
A charge registered on 10 Mar 2022 via Charge ID 100555031 with Hdfc Bank Limited was fully satisfied on 21 Aug 2025.
AGM
Ngl Fine-Chem Limited last Annual general meeting of members was held on 19 Aug 2025 as per latest MCA records.
Ceased
Jayaram Sitaram ceased to be Director.
Appointed
Sudhir Ramchandra Deo was appointed as Director.
Charges
A charge with Others of Rs. 50.50 Cr registered on 02 Aug 2022 with Charge ID 100603458 was modified on 13 Mar 2025.
Charges
A charge registered on 30 Aug 2021 via Charge ID 100476181 with Hdfc Bank Limited was fully satisfied on 06 Feb 2025.
Charges
A charge with Hdfc Bank Limited of Rs. 67.00 Cr registered on 07 Dec 2015 with Charge ID 10613804 was modified on 01 Feb 2025.
Ceased
Milind Vasant Shinde ceased to be Director.
Appointed
Dhananjay Narendra Mungale was appointed as Director.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.25 Cr with Charge ID 100829654 was registered on 29 Nov 2023.
Ceased
Kumarapuram Venkateswaran Subramanian ceased to be Director.

75 earlier events are in the company report.

News

NGL Fine-Chem: Co Gets Notice From GST Department For Short Payment Of 61.8 Million; Response Due By October 22, 2026.
25 Sep 2026 · Exchange Update

Frequently asked questions

NGL Fine-Chem is an active public limited company based in Mumbai, Maharashtra, India. The company works in animal pharmaceuticals and healthcare, within the pharma industry. It was incorporated on 18 December 1981 (45+ years old) and is registered under CIN L24110MH1981PLC025884. Listed on BSE: 524774 and NSE: NGLFINE.

NGL Fine-Chem reported revenue of ₹500.95 Cr for FY 2025-26 (up 36% YoY) based on consolidated financials.

NGL Fine-Chem has 6 current directors:

The latest financial statements of NGL Fine-Chem on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 19 August 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of NGL Fine-Chem is 27AAACN4805H1ZM, registered in Maharashtra.

The CIN (Corporate Identification Number) of NGL Fine-Chem is L24110MH1981PLC025884. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. NGL Fine-Chem is a listed company as per MCA records. Its shares are listed on both BSE (code: 524774) and NSE (symbol: NGLFINE).

NGL Fine-Chem has 12 court cases on record: 5 filed by the company and 7 filed against it. 5 are pending. Most are in the district courts.

NGL Fine-Chem was incorporated on 18 December 1981, making it 45+ years old. It is registered with the Registrar of Companies, Mumbai.

NGL Fine-Chem has 4 deals on record (4 market trades); the latest was in April 2016.

The peers of NGL Fine-Chem by revenue are Zim Laboratories Limited, Rajasthan Antibiotics Ltd, Marc Laboratories Limited, Caplin Steriles Limited, Unicure India Ltd and 4 more, all in the Pharma industry (Animal Pharma, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Jayaram Sitaram ceased to be Director on 04 Aug 2025. Sudhir Ramchandra Deo was appointed as Director on 22 May 2025. Milind Vasant Shinde ceased to be Director on 31 Mar 2024. NGL Fine-Chem has 20 board changes on record in total.